MINERVA NEUROSCIENCES INC
NERVNASDAQTrading Snapshot
- Day Range
- $3.35 – $3.42
- 52-Week Range
- $2.06 – $12.46
- Volume
- $1.93B
- Avg Volume
- $2.13B
- Shares Outstanding
- 46.6M
- Next Earnings
- Dec 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $18M
- Last Q Revenue
- $4M
- P/E Ratio
- -0.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-8.46
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +46.9%
Why Investors Own NERV
- ✓High-growth profile — revenue up +19.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MINERVA NEUROSCIENCES INC
NERV
StockOtter · stockotter.spaceAbout MINERVA NEUROSCIENCES INC
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorder
Analysts Set Minerva Neurosciences, Inc (NASDAQ:NERV) Target Price at $10.50
Minerva Neurosciences, Inc (NASDAQ: NERV - Get Free Report) has been assigned an average rating of "Reduce" from the four brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts hav
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the confirmator